Ponatinib is a potent oral kinase inhibitor indicated for the treatment of specific types of leukemia and chronic myeloid leukemia, with particularly remarkable efficacy in patients harboring the T315I mutation.

I. Indications

1. Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Ponatinib is indicated for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), including the following subgroups:

(1) Newly diagnosed Ph+ ALL: For use in combination with chemotherapy. This indication received accelerated approval based on achievement of minimal residual disease-negative complete remission at the end of induction therapy. Marketing authorization will be maintained only after confirmatory trials verify clinical benefit.

(2) Monotherapy: For Ph+ ALL patients who are ineligible for other kinase inhibitors, or patients with T315I mutation-positive Ph+ ALL.

2. Chronic Myeloid Leukemia

Ponatinib is indicated for adult patients with chronic myeloid leukemia (CML) as follows:

(1) Chronic phase CML (CP-CML): Patients with resistance or intolerance to at least two prior kinase inhibitors.

(2) Accelerated phase (AP-CML) or blast phase CML (BP-CML): Patients ineligible for other kinase inhibitors.

(3) T315I mutation-positive CML (including chronic, accelerated, and blast phases).

3. Important Limitations of Use

(1) Ponatinib is not indicated for patients with newly diagnosed chronic phase CML.

(2) Clinical trials demonstrated that monotherapy with 45 mg once daily in this patient population was associated with a twofold higher risk of severe adverse events compared with imatinib. The trial was terminated early due to safety concerns.

II. Contraindications and Dietary Restrictions

1. Contraindications

According to FDA prescribing information, ponatinib has no absolute contraindications. Nevertheless, given its severe adverse event profile, use should be exercised with caution or avoided in the following circumstances:

(1) Newly diagnosed chronic phase CML (not recommended).

(2) Hypersensitivity to ponatinib or any excipients of the preparation.

(3) History of severe uncontrolled cardiovascular disease (benefit-risk assessment is required prior to use).

2. Restricted Food

Grapefruit and grapefruit juice: Grapefruit consumption and grapefruit juice intake must be avoided throughout the treatment period.

3. Concomitant Medications to Be Avoided

(1) Strong CYP3A inhibitors (e.g., ketoconazole, itraconazole, clarithromycin): Concomitant use is contraindicated. If co-administration is unavoidable, the ponatinib dosage must be reduced.

(2) Strong CYP3A inducers (e.g., rifampin, carbamazepine, phenytoin): Concomitant use should be avoided, as it may reduce the therapeutic efficacy of ponatinib.

III. Special Population Use

1. Pregnant Women

(1) Ponatinib may cause fetal harm.

(2) In animal reproduction studies, administration of ponatinib to pregnant rats during the organogenesis period induced embryo-fetal toxicity at systemic exposures lower than the recommended human dose.

(3) Females of reproductive potential are advised to adopt effective contraception during treatment and for 3 weeks after the last dose.

2. Lactating Women

(1) Data regarding the excretion of ponatinib into human breast milk are unavailable.

(2) Considering the potential risk of severe adverse reactions in breastfed infants, lactation is not recommended during treatment and for 1 week after the last dose.

3. Females of Reproductive Potential

(1) Pregnancy testing: Pregnancy status must be confirmed prior to treatment initiation.

(2) Contraception: Effective contraception is required during treatment and for 3 weeks after the last dose.

(3) Fertility: Animal data indicate that ponatinib may impair female fertility; the reversibility of such effects remains unknown.

4. Patients with Hepatic Impairment

(1) Monotherapy (CP-CML, AP-CML, BP-CML, Ph+ ALL): For patients with pre-existing hepatic impairment (Child-Pugh Class A, B, or C), the starting dose shall be reduced from 45 mg to 30 mg once daily.

(2) Combination chemotherapy for newly diagnosed Ph+ ALL: No dosage adjustment is required in patients with mild hepatic impairment. Clinical data in patients with moderate to severe hepatic impairment are insufficient, and close monitoring is advised.

5. Elderly Patients

(1) Patients aged 65 years and older are more susceptible to adverse events including vascular occlusive events, thrombocytopenia, peripheral edema, and dyspnea.

(2) In the OPTIC trial, the 12-month molecular remission rate was lower in patients ≥65 years (27%) compared with those <65 years (47%), while the incidence of arterial occlusive events was significantly higher in the older group (38% vs 14%).

(3) Dosage selection should be undertaken with caution in elderly patients.

6. Pediatric Patients

The safety and efficacy of ponatinib in pediatric patients have not been established.

7. Patients with Renal Impairment

(1) Mild to moderate renal impairment has no clinically significant impact on the pharmacokinetics of ponatinib.

(2) No studies have been conducted in patients with severe renal impairment. Renal excretion is not the primary elimination pathway; however, potential effects on hepatic clearance remain undetermined.